Trans healthcare access in Iraq tightening — pharmacy compliance shift since Law 14
Following the passage of Law No. 14 in April 2024, the collective and partners have observed and received reports of changes in how Iraqi pharmacies handle hormone medications used in gender-affirming care. The changes are not uniform; some pharmacies operate as before, others have become noticeably more cautious.
What we are seeing
1. Increased prescription enforcement
Pharmacies in some cities — particularly Baghdad, Basra, and Najaf — that previously sold estradiol (Estrofem), cyproterone acetate (Androcur, Androfarm), spironolactone, and bicalutamide over the counter or with informal request are now more frequently asking for a prescription. The medications themselves remain available in stock; the gating mechanism has changed.
2. مذخر (medical wholesaler) ordering
For pharmacies that don’t keep hormones in stock, the previously-reliable approach of asking the pharmacist to order from the مذخر within 1–3 days now sometimes encounters refusal or delay. Reports suggest some مذخر-level distributors are flagging hormone orders for review.
3. Pharmacy questions
Some pharmacies have started asking what the medication is for. “Hormonal imbalance,” “endometriosis,” or “prostate condition” remain workable cover stories — but the question itself is new and indicates increased awareness.
4. Doctor liability
Iraqi doctors who previously wrote informal prescriptions for trans patients now face personal criminal liability under Law 14’s provision against “biological sex change for non-medical reasons” — up to 3 years for the doctor. We have heard of several doctors who have stopped writing such prescriptions in 2024–2025.
5. Geographic variation
The changes are most pronounced in Baghdad, the south, and conservative provinces. Iraqi Kurdistan (Erbil, Sulaymaniyah, Duhok) has seen less change so far, though the federal law does apply there.
What this means for you
If you are currently on HRT through Iraqi pharmacies
- Build a buffer. When you can, buy 3–6 months of supply rather than month-by-month. Stockpiles reduce vulnerability to future disruption.
- Know multiple sources. Don’t depend on a single pharmacy. Spread purchases across 3–5 establishments so no single one knows your full pattern.
- Have backup plans. If your pharmacy refuses, have a list of alternatives. Some online sources (international pharmacies that ship to Iraq) remain available, though shipping is unreliable.
- Keep your medical records privately. If you ever need to explain hormone use to a non-Iraqi doctor (e.g., at the destination of asylum), having lab results and a documented timeline helps.
If you are starting HRT now
- Read all our HRT guides first — see HRT in Iraq overview, sourcing, pharmacy script, monitoring, and risks.
- Plan for monitoring. Iraqi private labs continue to run hormone panels (E2, T, prolactin, liver enzymes, potassium) without questions. Establish a relationship with one before starting.
- Factor in supply risk. Starting HRT means committing to long-term supply. If you cannot reliably source for 12+ months, the risks of intermittent or interrupted HRT are significant — see risks.
Cover stories that still work
The harm-reduction guides recommend specific Arabic scripts that have been tested. The “prostate cancer” framing for cyproterone (Androcur) and bicalutamide is still effective with most pharmacists because both medications have legitimate uses for that condition. The “menopause” framing for estradiol is still effective for older patients.
For the full scripts in Arabic and English, see Pharmacy Script.
What we don’t yet know
- How long the current shift lasts. Pharmacy practices in Iraq have changed before in response to political pressure and reverted when pressure eased.
- Whether any prosecutions of doctors or pharmacists under Law 14 have actually occurred. We are watching for this.
- Whether the مذخر distribution-level scrutiny is policy or individual-discretion-driven.
We will update this alert as more information becomes available. If you have direct experience — recent pharmacy interactions, prescription requests, or refusals — please report it confidentially. Your reports help calibrate our guidance.